Cargando…

EZH2 Promotes Malignant Behaviors via Cell Cycle Dysregulation and Its mRNA Level Associates with Prognosis of Patient with Non-Small Cell Lung Cancer

BACKGROUND: Epigenetic silencing is a common mechanism to inactivate tumor suppressor genes during carcinogenesis. Enhancer of Zeste 2 (EZH2) is the histone methyltransferase subunit in polycomb repressive complex 2 which mediates transcriptional repression through histone methylation. EZH2 overexpr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cao, Wei, Ribeiro, Rachel de Oliveira, Liu, Diane, Saintigny, Pierre, Xia, Ronghui, Xue, Yuwen, Lin, Ruxian, Mao, Li, Ren, Hening
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3534094/ https://www.ncbi.nlm.nih.gov/pubmed/23300840 http://dx.doi.org/10.1371/journal.pone.0052984

Ejemplares similares

Overexpression of EZH2 in multiple myeloma is associated with poor prognosis and dysregulation of cell cycle control
por: Pawlyn, C, et al.
Publicado: (2017)

CDC25A(Q110del): A Novel Cell Division Cycle 25A Isoform Aberrantly Expressed in Non-Small Cell Lung Cancer
por: Younis, Rania H., et al.
Publicado: (2012)

RCC1 functions as a tumor facilitator in clear cell renal cell carcinoma by dysregulating cell cycle, apoptosis, and EZH2 stability
por: Wu, Yunfei, et al.
Publicado: (2023)

Dysregulated lipid metabolism blunts the sensitivity of cancer cells to EZH2 inhibitor
por: Zhang, Tengrui, et al.
Publicado: (2022)

Divergent Effects of EZH1 and EZH2 Protein Expression on the Prognosis of Patients with T-Cell Lymphomas
por: Schümann, Franziska Lea, et al.
Publicado: (2021)

EZH2 dysregulation: Potential biomarkers predicting prognosis and guiding treatment choice in acute myeloid leukaemia
por: Chu, Ming‐qiang, et al.
Publicado: (2019)

EZH2 in Myeloid Malignancies
por: Rinke, Jenny, et al.
Publicado: (2020)

Dual targeting of EZH1 and EZH2 for the treatment of malignant rhabdoid tumors
por: Shinohara, Haruka, et al.
Publicado: (2022)

Cell Cycle Dysregulation and Renal Fibrosis
por: Wu, Yun-Shan, et al.
Publicado: (2021)

LncRNA GAS5 regulates redox balance and dysregulates the cell cycle and apoptosis in malignant melanoma cells
por: Chen, Long, et al.
Publicado: (2018)

EZH2 in normal hematopoiesis and hematological malignancies
por: Herviou, Laurie, et al.
Publicado: (2015)

Both EZH2 and JMJD6 regulate cell cycle genes in breast cancer
por: Biswas, Antara, et al.
Publicado: (2020)

Polycomb EZH1 regulates cell cycle/5‐fluorouracil sensitivity of neuroblastoma cells in concert with MYCN
por: Shinno, Yoshitaka, et al.
Publicado: (2022)

Dysregulated Recruitment of the Histone Methyltransferase EZH2 to the Class II Transactivator (CIITA) Promoter IV in Breast Cancer Cells
por: Truax, Agnieszka D., et al.
Publicado: (2012)

Dysregulated Expression of Long Non-Coding RNA MINCR and EZH2 in Colorectal Cancer
por: Cheraghi, Sajjad, et al.
Publicado: (2022)

A Cell Cycle-Related 13-mRNA Signature to Predict Prognosis in Hepatocellular Carcinoma
por: Zhou, Yang, et al.
Publicado: (2022)

∆ DNMT3B4-del Contributes to Aberrant DNA Methylation Patterns in Lung Tumorigenesis
por: Ma, Mark Z., et al.
Publicado: (2015)

Dysregulation of Small Nucleolar RNAs in B-Cell Malignancies
por: Verbeek, Martijn W. C., et al.
Publicado: (2022)

Expression of EZH2 in uveal melanomas patients and associations with prognosis
por: Cheng, Ying, et al.
Publicado: (2017)

EZH2 overexpression is associated with poor prognosis in patients with glioma
por: Zhang, Yanyang, et al.
Publicado: (2016)

The correlation of EZH2 expression with the progression and prognosis of hepatocellular carcinoma
por: Wu, Shi-yi, et al.
Publicado: (2022)

Benefits and Challenges of Inhibiting EZH2 in Malignant Pleural Mesothelioma
por: Al Khatib, MHD Ouis, et al.
Publicado: (2023)

Analysis of the correlation between Zeste enhancer homolog 2 (EZH2) mRNA expression and the prognosis of mesothelioma patients and immune infiltration
por: Fan, Kui, et al.
Publicado: (2022)

EZH2 as a prognostic-related biomarker in lung adenocarcinoma correlating with cell cycle and immune infiltrates
por: Fan, Kui, et al.
Publicado: (2023)

Cell-Cycle Dysregulation in the Pathogenesis of Diabetic Kidney Disease: An Update
por: Deng, Bowen, et al.
Publicado: (2023)

Dysregulation of KIF14 regulates the cell cycle and predicts poor prognosis in cervical cancer: a study based on integrated approaches
por: Xiao, Li, et al.
Publicado: (2021)

Clinicopathological significance of EZH2 mRNA expression in patients with hepatocellular carcinoma
por: Sudo, T, et al.
Publicado: (2005)

The Cell Cycle in Malignancy and Immunity
por: Lord, B. I.
Publicado: (1975)

Mast cells dysregulate apoptotic and cell cycle genes in mucosal squamous cell carcinoma
por: Ch'ng, Sydney, et al.
Publicado: (2006)

Long non-coding RNA HOTAIR promotes glioblastoma cell cycle progression in an EZH2 dependent manner
por: Zhang, Kailiang, et al.
Publicado: (2014)

Mutations in EZH2 are associated with poor prognosis for patients with myeloid neoplasms
por: Zhang, Qi, et al.
Publicado: (2019)

EZH2/H3K27Me3 and phosphorylated EZH2 predict chemotherapy response and prognosis in ovarian cancer
por: Sun, Si, et al.
Publicado: (2020)

EZH2 is a sensitive marker of malignancy in salivary gland tumors
por: Hajósi-Kalcakosz, Szofia, et al.
Publicado: (2015)

Redistribution of EZH2 promotes malignant phenotypes by rewiring developmental programmes
por: Mortimer, Thomas, et al.
Publicado: (2019)

EZH2 abnormalities in lymphoid malignancies: underlying mechanisms and therapeutic implications
por: Li, Boheng, et al.
Publicado: (2019)

Exosomal circRNA_100284 from arsenite-transformed cells, via microRNA-217 regulation of EZH2, is involved in the malignant transformation of human hepatic cells by accelerating the cell cycle and promoting cell proliferation
por: Dai, Xiangyu, et al.
Publicado: (2018)

Drug Targets for Cell Cycle Dysregulators in Leukemogenesis: In Silico Docking Studies
por: Jayaraman, Archana, et al.
Publicado: (2014)

Regulation of T Cell Differentiation and Function by EZH2
por: Karantanos, Theodoros, et al.
Publicado: (2016)

EZH2 Expression is increased in BAP1-mutant renal clear cell carcinoma and is related to poor prognosis
por: Sun, Chenmin, et al.
Publicado: (2018)

Tyro3 Targeting as a Radiosensitizing Strategy in Bladder Cancer through Cell Cycle Dysregulation
por: Silina, Linda, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_09lbgju0nc0b81vmop8llr4chf